Antiangiogenic effects of a protein kinase Cβ-selective small molecule

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 1, 2002, Pages 69-77

  Teicher, B A ^a   Alvarez, E ^a   Menon, K ^a   Esterman, M A ^a   Considine, E ^a   Shih, C ^a   Faul, M M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antiangiogenic agent; Corneal micropocket assay; Intratumoral vessels; Protein kinase C (PKC )

Indexed keywords

ANGIOGENESIS INHIBITOR; BISINDOLYLMALEIMIDE; CARBOPLATIN; FIBROBLAST GROWTH FACTOR; PACLITAXEL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; VASCULOTROPIN; BASIC FIBROBLAST GROWTH FACTOR; PROTEIN KINASE C BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER TRANSPLANTATION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; LUNG SMALL CELL CANCER; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UMBILICAL VEIN; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CELL CULTURE; DOSE RESPONSE; ENDOTHELIUM CELL; NUDE MOUSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AORTA, THORACIC; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SMALL CELL; CORNEA; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; PROTEIN KINASE C; RATS; RATS, INBRED F344; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036137647     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-001-0386-2     Document Type: Article

References (78)

1. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells
2. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
3. An improved purification procedure and properties of casein kinase II from brain
4. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-lb (RSK-2) and p70 S6 kinase
5. A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth
6. Protein kinase C and tumorigenic potential
7. The involvement of novel protein kinase C isozymes in influencing sensitivity of breast cancer MCF-7 cells to tumor necrosis factor-α
8. Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C
9. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells
10. Inhibitors of protein kinase C and related receptors for the lipophilic second-messenger sn-l,2-diacylglycerol
11. Therapeutic potential of protein kinase C inhibitors
12. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
13. Protein kinase C: A worthwhile target for anticancer drugs?
14. Modulation of intracellular second messengers by dietary fat during colonic tumor development
15. Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro
16. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531
17. Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A
18. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
19. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
20. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
21. L-Dopa decarboxylase activity (DDC): A distinguishing biomarker for the growth of small-cell lung cancer (SCCL) in tissue culture
22. Effects of dibutyral cyclic adenosine 3′,5′-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase
23. Effect of host microenvironment on the micro-circulation of human colon adenocarcinoma
24. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo
25. Molecular basis of targeted chemotherapy: Novel concepts with special reference to the treatment of Hodgkin's disease
26. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation
27. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C
28. The potential for isoenzyme-selective modulation of protein kinase C
29. Recent discovery and development of selective protein kinase C inhibitors
30. Angiogenesis: A dynamic balance of stimulators and inhibitors
31. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
32. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus
33. The Eugene M. Landis award lecture 1996. Delivery of molecular and cellular medicine to solid tumors
34. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohex-adecene-l,3(2H)- dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta
35. Dynamics of tumor oxygenation. CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
36. A calcium/calmodulin-dependent protein kinase from mammalian brain that phosphorylates Synapsin I: Partial purification and characterization
37. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response
38. Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety
39. The Jak/Stat signaling cascade
40. Geometric resistance and microvascular network architecture of human colorectal carcinoma
41. Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin
42. Multiple biological responses activated by nuclear protein kinase C
43. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go6976
44. VEGF receptor signaling in tumor angiogenesis
45. Angiogenic factors as tumor markers
46. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
47. Angiogenesis: New aspects relating to its initiation and control
48. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
49. The distinct biological potential of PKC isotypes
50. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
51. Indolocarbazoles as anti-cancer agents
52. What, if anything, is an angiogenic factor?
53. Overcoming drug resistance in lung cancer
54. The phosphorylated 1169-tyrosine containing region of fit-1 kinase (VEGFR-1) is a major binding site for PLCgamma
55. Protein kinase C: A novel target for inhibiting gastric cancer cell invasion
56. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells
57. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/flk-1 receptor and protein kinase C signaling pathway
58. Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells
59. Regulation of tumor angiogenesis by organ-specific cytokines
60. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
61. The activity and expression of thymidine phosphorylase in human solid tumours
62. ++ dependent kinase
63. A systems approach to cancer therapy
64. Enzymatic rationale and preclinical support for a potent protein kinase Cb inhibitor in cancer therapy
65. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts
66. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human hepatocellular and gastric cancer xenografts
67. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in murine Lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts
68. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
69. Clinical significance of the determination of angiogenic factors
70. The bisindolylmaleimide GF 109203X is a potent selective inhibitor of protein kinase C
71. Identification of PKC-isoform-specific biological actions using pharmacological approaches
72. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
73. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
74. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
75. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis
76. Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells
77. Overexpression of protein kinase C-bl isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells